Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 1Myelodysplastic-Myeloproliferative Diseases 1Immune Checkpoint Inhibitors (ICI)-Related Dermatitis 1

Interventions

Specimen Handling 7Biopsy 6Cyclophosphamide 5ruxolitinib 4Mycophenolic Acid 4Busulfan 4fludarabine phosphate 3fludarabine 3Whole-Body Irradiation 3Tacrolimus 3Melphalan 3Injections 3Decitabine 3Cyclosporine 3Azacitidine 3venetoclax 2decitabine and cedazuridine drug combination 2Sirolimus 2Methotrexate 2Granulocyte Colony-Stimulating Factor 2veliparib 1tocilizumab 1tagraxofusp 1posaconazole 1peginterferon alfa-2b 1onvansertib 1merphos 1iadademstat 1gilteritinib 1fedratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic-Myeloproliferative Diseases × Janus Kinase Inhibitors × 1 year × Clear all
NCT07228624 2026-02-19

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Fred Hutchinson Cancer Center

Phase 2 Recruiting
50 enrolled
Myeloid

Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡